Skip to main content
eScholarship
Open Access Publications from the University of California

A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib

  • Author(s): Lucero, Olivia M
  • Fitzmaurice, Sarah
  • Thompson, Curtis
  • Leitenberge, Justin
  • et al.
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License
Abstract

Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is lacking. We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. Complete histologic clearance of a tumor in a recurrent, infiltrative, and sclerosing basal cell carcinoma with vismodegib is uncommon.

Main Content
Current View